biomed devic servic
new ceo say right thing feel
bottom line new ceo bryan hanson said right thing first quarterli call
encourag candor outlin oper cultur
challeng compani must address move forward mr hanson highlight
potenti risk current timelin allevi supply/manufactur issu
previous exit stress time invest necessari rebuild
trust commerci channel physician custom key
top-lin growth may disappoint lack full-year guidanc
mute near-term growth expect believ compani took right approach
elect wait call outlin broader plan sum
surpris long-term investor start opportunist build posit
next particularli given view limit downsid risk howev
messag regard timelin suppli new product turnaround sale
momentum start increasingli feel like event reiter hold given
expect share remain range-bound top-lin growth look
challeng supply/manufactur issu weigh margin next
top line post revenu cg/street estim
suppli issu continu weigh out-performance driven
stronger anticip procedur volum stock order apac --
expect weigh growth nonetheless apac
highlight xfx growth xfx hip continu benefit
weight legaci zimmer product less affect suppli issu
emea america came expect xfx xfx
respect still under-perform market inventori constraint key legaci
biomet product continu impact compani abil fulfil exist demand
manufactur manag note continu make progress
manufacturing/suppli mr hanson note risk opportun
previou timelin specif manag highlight complex
on-going process could lead delay remedi
manufactur constraint compani continu work consult refin
manufactur process well outsid vendor dual-sourc manufactur
key product howev feel like issu may persist
continu think manufactur issu eventu resolv remain cautiou
given uncertainti surround time cadenc recaptur lost custom
guidanc given limit tenur new ceo on-going complexity/uncertainti
surround remedi suppli constraint compani elect wait
result issu full-year guidanc manag provid revenu
guidanc y/i growth xfx pro
forma ep guidanc
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
pipelin updat manag reiter expect pipelin product
play import part compani return sustain revenu earn
growth note zimmer highlight persona partial knee soft-launch
well launch persona tm tibia knee cementless persona
revis knee med-tech rosa robot track limit releas
view pipelin posit howev expect take
least product materi impact top-lin growth
zimmer report sale street
revenu support higher anticip hip/kne volum
us distributor stock order asia pacif quarter ahead
expect compani note continu lose share key us hip/kne
market given suppli constraint addit qualiti remedi effort
manufacturing/suppli issu continu impact margin due higher product cost
includ dual sourc inventori outsid vendor invest
end gross margin came y/i pro forma
oper margin y/i zimmer report adjust ep
exclud one-tim benefit reduct defer tax liabil
result us tax reform compar our/consensu estim
figur result vs estim consensu
biomed devic servic
overal performanceactualcg estimatebeat/miss beat/miss consensusbeat/missnet good gross pro-forma oper net revenu productactualcg estimatebeat/miss beat/miss growthnet revenu geographyactualcg estimatebeat/miss beat/miss growthnet zimmer biomet hold
updat guidanc chang estim
given short tenur zimmer new ceo bryan hanson uncertainti
surround remedi suppli issu compani issu full year
financi guidanc said provid revenu guidanc
repres y/i growth xfx pro forma
ep guidanc furthermor manag note expect
revenu growth acceler year make progress toward
restor suppli launch new product help compani regain market
share tax perspect zimmer guid forward tax rate rang
caution plan reinvest major tax save
back busi made follow chang estim
adjust revenu estim
pro forma ep estim
adjust revenu estim
maintain pro forma ep estim
adjust revenu estim
pro forma ep estim
adjust revenu estim
pro forma ep estim
adjust revenu estim
pro forma ep estim
adjust revenu estim
pro forma ep estim
figur chang estim
broad large-cap med-tech group current trade mean price-to-earnings multipl
valu zimmer discount large-cap med-tech group given
uncertainti surround remedi suppli issu impact revenu
margin sum lower price target base price-to-earnings multipl
appli pro-forma ep
biomed devic servic
figur matrix discount rate impli share price target
zimmer biomet
zimmer world-wide leader design develop manufactur market
reconstruct spinal implant trauma relat orthoped surgic product
biomed devic servic
comp pe multipl price metric use price-to-earnings valuat analysisbroad large-cap medic devic price-to-earnings multipl adjust pro-forma figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
biomed devic servic
zimmer biomet incom statementcanaccord genuiti kyle except per share good devic gener asset op incom chg chg amort stk incom minor incom ep ep one-tim ep chg share gener oper rate adjust growth growth ep ex compani document canaccord genuiti estim figur pro forma revenu build
biomed devic servic
zimmer biomet revenu buildcanaccord genuiti kyle euro yen fx impact impact fx growth growth zimmer biomet hold
